Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind Phase 3 trial of dapagliflozin in youth with type 2 diabetes mellitus
2015-005041-31Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin 10 mg add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in glycated haemoglobin (HbA1c) at Week 24. Started Apr 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-005041-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005041-31.